SEARCH

SEARCH BY CITATION

References

  • 1
    Di Bisceglie AM. Hepatitis C. Lancet 1998; 351:35155.
  • 2
    Marcellin P. Hepatitis C: the clinical spectrum of the disease. J Hepatol 1999; 31(Suppl 1):916.
  • 3
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Schiffman M, Reindollar R, Goodman ZD, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358:958965.
  • 4
    Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonzales FL, Häussinger D, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New Engl J Med 2002; 347:975982.
  • 5
    Zeuzem S, Feinmann SV, Rasenack J, Heathcote EJ, Lai M-Y, Gane E, O'Grady J, et al. Peg-Interferon alfa-2a in patients with chronic hepatitis C. New Engl J Med 2000; 343:16661672.
  • 6
    Dolin R, Reichman RC, Madore HP, Maynard R, Linton PN, Webber-Jones J. A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. New Engl J Med 1982; 307:580584.
  • 7
    Hay AJ, Wolstenholme AJ, Skehel JJ, Smith MH. The molecular basis of the specific anti-influenza action of amantadine. EMBO J 1985; 4:30213024.
  • 8
    Wang C, Takeuchi K, Pinto LH, Lamb RA. Ion channel activity of influenza A virus M2 protein: characterization of the amantadine block. J Virol 1993; 67:55855594.
  • 9
    Oxford JS, Schild GC. In vitro inhibition of rubella virus by 1-adamantanamine hydrochloride. Arch Gesamte Virusforsch 1965; 17:313329.
  • 10
    Kato N, Eggers HJ. Inhibition of uncoating of fowl plague virus by l-adamantanamine hydrochloride. Virology 1969; 37:632641.
  • 11
    Pfau CJ, Trowbridge RS, Welsh RM, Staneck LD, O'Connell CM. Arenaviruses: inhibition by amantadine hydrochloride. J Gen Virol 1972; 14:209211.
  • 12
    Koff WC, Elm Inhibition of dengue virus replication by amantadine hydrochloride. Antimicrob Agents Chemother 1980; 18:125129.
  • 13
    Leibowitz JL, Reneker SJ. The effect of amantadine on mouse hepatitis virus replication. Adv Exp Med Biol 1993; 342:117122.
  • 14
    Martin J, Navas S, Fernandez M, Rico M, Pardo M, Quiroga JA, Zahm F, et al. In vitro effect of amantadine and interferon alpha-2a on hepatitis C virus markers in cultured peripheral blood mononuclear cells from hepatitis C virus-infected patients. Antiviral Res 1999; 42:5970.
  • 15
    Smith JP. Treatment of chronic hepatitis C with amantadine. Dig Dis Sci 1997; 42:16811687.
  • 16
    Younossi ZM, Perrillo, RP. The roles of amantadine, rimantadine, ursodeoxycholic acid, and NSAIDs, alone or in combination with alpha interferons, in the treatment of chronic hepatitis C. Semin Liver Dis 1999; 19(Suppl 1):95102.
  • 17
    Tabone M, Ercole E, Zaffino C, Sallio Bruno F, Pera A, Bonino F. Amantadine hydrochloride decreases serum ALT activity without effects on serum HCV-RNA in chronic hepatitis C patients. Ital J Gastroenterol Hepatol 1998; 30:611613.
  • 18
    Craxi A, Lo Iacono O. Amantadine for chronic hepatitis C: a magic bullet or yet another dead duck? J Hepatol 2001; 35:527530.
  • 19
    Zeuzem S, Teuber G, Naumann U, Berg T, Raedle J, Hartmann S, Hopf U. Randomized, double-blind, placebo-controlled trial of interferon alfa2a with and without amantadine as initial treatment for chronic hepatitis C. Hepatology 2000; 32:835841.
  • 20
    Mangia A, Minerva N, Annese M, Leandro G, Villani MR, Santoro R, Carretta V, et al. A randomized trial of amantadine and interferon versus interferon alone as initial treatment for chronic hepatitis C. Hepatology 2001; 33:989993.
  • 21
    Caronia S, Bassendine MF, Barry R, Mills P, Naoumov NV, Fox R, Lowes J, et al. Interferon plus amantadine versus interferon alone in the treatment of naive patients with chronic hepatitis C: a UK multicentre study. J Hepatol 2001; 35:512516.
  • 22
    Tabone M, Laudi C, Delmastro B, Biglino A, Andreoni M, Chieppa F, Bonardi R, et al. Interferon and amantadine in combination as initial treatment for chronic hepatitis C patients. J Hepatol 2001; 35:517521.
  • 23
    Helbling B, Stamenic I, Viani F, Gonvers J-J, Dufour J-F, Reichen J, Cathomas G, et al. Interferon and amantadine in naive chronic hepatitis C: a double-blind, randomized, placebo-controlled trial. Hepatology 2002; 35:447454.
  • 24
    Brillanti S, Levantesi F, Masi L, Foli M, Bolondi L. Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C. Hepatology 2000; 32:630634.
  • 25
    Berg T, Naumann A, Wiedenmann B, Hopf U. Pilot study of interferon-alfa high-dose induction therapy in combination with ribavirin plus amantadine for nonresponder patients with chronic hepatitis C. Z Gastroenterol 2001; 39:145151.
  • 26
    Scheuer PJ. Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 1991; 13:327374.
  • 27
    Desmet V, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading, and staging. Hepatology 1994; 19:15131520.
  • 28
    Mangia A, Leandro G, Helbling B, Renner EL, Tabone M, Caronia S, Forster GR, et al. Combination therapy with amantadine and interferon in naive patients with chronic hepatitis C: meta-analysis of individual patient data from 6 clinical trials [Abstract]. Hepatology 2002; 36:570.
  • 29
    McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339:14851492.
  • 30
    Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352:14261432.
  • 31
    Torre F, Rosella G, Grasso A, Brizzolara R, Campo N, Sinelli N, Balestra V, et al. Clearance kinetics of hepatitis C virus under different antiviral therapies. J Med Virol 2001; 64:455459.
  • 32
    Griffin SDC, Beales LP, Clarke DS, Worsfold O, Evans SD, Jaeger J, Harris MPG, et al. The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug, amantadine. FEBS Lett 2003; 535:3438.
  • 33
    Carithers RLJ, Zeuzem S, Manns MP, McHutchison JG, Perrillo RP, Bailey R, Ling M-H, et al. Multicenter, randomized, controlled trial comparing high-dose daily induction interferon plus ribavirin versus standard interferon alfa-2b plus ribavirin [Abstract]. Hepatology 2000; 32:317.
  • 34
    Berg T, Hopf U, Stark K, Baumgarten R, Lobeck H, Schreier E. Distribution of hepatitis C virus genotypes in German patients with chronic hepatitis C: correlation with clinical and virological parameters. J Hepatol 1997; 26:484491.
  • 35
    McOmish F, Chan SW, Dow BC, Gillon J, Frame WD, Crawford RJ, Yap PL, et al. Detection of three types of hepatitis C virus in blood donors: investigation of type-specific differences in serologic reactivity and rate of alanine aminotransferase abnormalities. Transfusion 1993; 33:713.
  • 36
    Berg T, Sarrazin C, Herrmann E, Hinrichsen H, Gerlach T, Zachoval R, Wiedenmann B, et al. Prediction of treatment outcome in patients with chronic hepatitis C: significance of baseline parameters and viral dynamics during therapy. Hepatology 2003; 37:600609.
  • 37
    EASL International Consensus Conference on hepatitis C. Paris, 26–27 February 1999. Consensus statement. J Hepatol 1999; 31(Suppl 1):38.